معرفی
Christen Chisholm is an Associate Research Fellow at the University of Wollongong, working within the Faculty of Science, Medicine and Health, School of Science. Appointed on January 1, 2024, for a two-year term through December 31, 2025, Dr. Chisholm focuses on neurodegenerative disease research, particularly amyotrophic lateral sclerosis (ALS).
Dr. Chisholm's research centers on the molecular mechanisms underlying ALS, with particular emphasis on:
- Protein misfolding and aggregation in neurodegenerative diseases
- Ubiquitin-proteasome system and proteostasis
- SOD1 protein pathology in ALS
- Therapeutic strategies targeting protein homeostasis
- Mechanisms of motor neuron vulnerability in ALS
- Preclinical development of combination therapies
Analysis of Dr. Chisholm's research outputs reveals a consistent focus on understanding the molecular basis of ALS, particularly examining how protein misfolding and disruption of protein homeostasis contribute to disease pathology. Their work spans from basic molecular mechanisms to preclinical therapeutic development, with recent publications exploring polytherapy approaches for SOD1-associated ALS. The research demonstrates a progression from fundamental investigations of protein aggregation mechanisms to applied therapeutic strategies, indicating a translational research trajectory with direct implications for clinical treatment approaches.
Dr. Chisholm has received significant research funding, including:
- FightMND Drug Development Grant
- Australian National Health and Medical Research Council (NHMRC) Investigator Grant (No. 1194872)
- Motor Neuron Disease Research Institute of Australia Bill Gole Postdoctoral Fellowship
While specific students advised by Dr. Chisholm are not mentioned in the available information, their research appears to be conducted within collaborative teams focused on ALS research. The publications indicate work with multiple co-investigators across various institutions, suggesting active participation in the broader ALS research community. Dr. Chisholm's research program appears well-funded and productive, with multiple publications in high-impact journals including EBioMedicine, Scientific Reports, and iScience.
Dr. Chisholm's work is conducted within research teams investigating neurodegenerative diseases, with particular focus on ALS mechanisms and therapeutics. The research utilizes both cellular and animal models of disease, with recent work focusing on combination therapies for SOD1-associated ALS. The collaborative nature of the publications suggests integration within larger research networks focused on understanding and treating motor neuron diseases, contributing to the growing body of knowledge aimed at developing effective treatments for this devastating condition.
